An interventional study of Croma revitalis in Skin Smoothness, sponsored by Croma-Pharma GmbH. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Croma-Pharma GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the effects and safety of croma revitalis in improving midface (cheek area) skin smoothness
Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Croma revitalis is a (CE)-marked, non-active, single-use hyaluronic acid-based medical device, intended for intradermal administration in the midface (cheek area).
Device: Croma revitalis
Croma revitalis is a hyaluronic acid-based injectable gel for soft tissue implantation and intradermal aesthetic use. 1 mL per cheek side per treatment session, distributed across 4 intradermal injection points (0.25 mL each) using a standardized injection technique with a sterile needle at baseline Week 0, Week 3, and Week 6. After week 6 a follow up period until week 30 is performed at week 9, 12, 16, 20, 24 and 30.
Skin Smoothness: Responder status assessed by independent evaluator at site
Responder status as assessed by a live independent evaluator at site using the validated Canfield Skin Quality Scale - Skin Smoothness (CSQS-SS)
Time frame: week 12
Skin Smoothness: Responder status assessed by independent evaluator at site - other timepoints
To evaluate improvement in midface (cheek area) skin smoothness using the validated CSQS-SS at additional study timepoints, as assessed by a live independent evaluator at site
Time frame: week 9, week 16, week 20, week 24, week 30
Skin Smoothness: Responder status assessed by blinded panel
To evaluate improvement in midface (cheek area) skin smoothness using the validated CSQS-SS at additional study timepoints, as assessed by a blinded panel of three independent evaluators via photographic review.
Time frame: week 9, week 12, week 16, week 20, week 24, week 30
Skin Smoothness: Change from Baseline assessed by independent evaluator at site
Change from baseline in CSQS-SS scores based on assessment of both sides by a live independent evaluator at site
Time frame: Week 9, 12, 16, 20, 24 and 30
Skin Smoothness: Change from baseline assessed by blinded panel
Change from baseline in CSQS-SS scores based on the blinded panel of three independent evaluators via photographic review assessment
Time frame: Week 9, 12, 16, 20, 24 and 30
Cheek Lines: Responder Status assessed by independent evaluator at site
Responder status at follow-up time points based on CSQS-CL assessment by a live independent evaluator at site
Time frame: Week 9, 12, 16, 20, 24, and 30
Cheek Lines: Change from Baseline assessed by independent evaluator at site
Change from baseline in CSQS-CL scores based on assessment of both sides by a live independent evaluator at site.
Time frame: Week 9, 12, 16, 20, 24 and 30
Cheek Lines: Responder status assessed by blinded panel
Responder status at follow-up time points based on blinded panel of three independent evaluators via photographic review assessment using CSQS-CL.
Time frame: Week 9, 12, 16, 20, 24, and 30
Cheek Lines: Change from Baseline assessed by blinded panel
Change from baseline in CSQS-CL scores, based on the blinded panel of three independent evaluators via photographic review assessment
Time frame: Week 9, 12, 16, 20, 24 and 30
FACE-Q™ Satisfaction with Skin
Participant-reported outcomes using FACE-Q™ Satisfaction with Skin
Time frame: Week 9, 12, 16, 20, 24 and 30
FACE-Q™ Satisfaction with Outcome
Participant-reported outcomes using FACE-Q™ Satisfaction with Outcome
Time frame: Week 9, 12, 16, 20, 24 and 30
FACE-Q™Lines Appraisal
Participant-reported outcomes using FACE-Q™ Lines Appraisal
Time frame: Week 9, 12, 16, 20, 24 and 30
GAIS assessed by the participants
Global Aesthetic Improvement Scale (GAIS) assessed by the participants
Time frame: Week 9, 12, 16, 20, 24, and 30
GAIS assessed by an independent evaluator at site
Global Aesthetic Improvement Scale (GAIS) assessed by and independent evaluator at site
Time frame: Week 9, 12, 16, 20, 24, and 30
Skin hydration: change from baseline
Change from baseline in midface (cheek area) skin hydration as measured by corneometer
Time frame: Week 9, 12, 16, 20, 24, and 30
Skin elasticity: change from baseline
Change from baseline in midface (cheek area) skin elasticity as measured by cutometer
Time frame: Week 9, 12, 16, 20, 24, and 30
Skin firmness(tone): change from baseline
Change from baseline in midface (cheek area) skin firmness(tone) as measured by cutometer
Time frame: Week 9, 12, 16, 20, 24, and 30
Safety Events occurence
Occurrence, severity, and relationship to treatment of AEs, SAEs, and ADEs throughout the study
Time frame: From first treatment, up to 30 weeks after first treatment ( until study completion or withdrawal)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Oct 2027, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.